Disease Landscape and Forecast Insights

A growing number of clinically unique disease-modifying therapies (DMTs) have been approved for the treatment of relapsing forms of multiple sclerosis , the most prevalent form of MS. Nevertheless…

With more than a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and more in the pipeline, the treatment journey for U.S. MS patients continues…

The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants further shift the complicated treatment algorithm…

The dynamic multiple sclerosis (MS) market in the United States features more than a dozen high-cost branded (and one generic) disease-modifying therapies (DMTs) and an active pipeline. As the …

The shifting multiple sclerosis (MS) therapy market continues to evolve as new disease-modifying therapies (DMTs) expand treatment choices. Standout Ocrevus (Roche/Genentech) continues to transform…

With more than a dozen disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS), the treatment journey for MS patients is varied and complex. To date, the MS market has…

MARKET OUTLOOK Multiple Sclerosis (MS), a chronic immune-mediated disease of the nervous system, is classified as a rare disease in China because of its low prevalence in the country. Two…

With over a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and many more in the pipeline, the treatment journey for U.S. MS patients…

The multiple sclerosis (MS) therapy market comprises more than a dozen disease-modifying therapies (DMTs) spanning a range of mechanisms of action, clinical profiles, formulations, and value…

The treatment journey for multiple sclerosis (MS) patients in Europe is complicated and individualized, driven by the availability of a broad array of disease-modifying therapies (DMTs)—…

Market Outlook In the EU5, access to disease-modifying therapies (DMTs) for the treatment of multiple sclerosis is impacted by multiple factors including specific indication labeling, monitoring…

Market Overview In a landmark FDA ruling in March 2017, Ocrevus became the first disease-modifying therapy (DMT) approved for the treatment of primary-progressive multiple sclerosis (PP-MS)…